Vasomune Therapeutics Appoints Douglas A. Hamilton as President and Chief Executive Officer
October 09, 2018 08:00 ET
|
Vasomune Therapeutics
Toronto, ON, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Vasomune Therapeutics, a leading biotechnology company developing therapeutics targeting vascular dysfunction and inflammation, announced today Douglas...
Vasomune Therapeutics and AnGes, Inc. enter into a Multi-Million Dollar Global Co-Development Agreement to Advance an Innovative Platform Targeting Vascular Leakage
July 31, 2018 07:00 ET
|
AnGes, Inc.
Tokyo, Japan and Toronto, Ontario, July 31, 2018 (GLOBE NEWSWIRE) -- Vasomune Therapeutics (“Vasomune”), a Toronto-based spin-out from Sunnybrook Research Institute and MaRS Innovation, and AnGes,...